There are approximately 7,000 different types of rare disease and researchers estimate that there are more than 300 million people worldwide living with such a condition, according to the N
At Frontiers Health 2022, pharmaphorum Editor in Chief Jonah Comstock speaks with Sai Shankar and Pierre Leurent, co-presidents of Aptar Digital Health. They discuss their new part
AstraZeneca has moved a step closer to bringing a first-in-class drug to market in the US that can be used to reduce severe asthma attacks, after an FDA advisory committee voted in favour o
Australian digital health company Respiri has started to roll out its digital remote patient monitoring (RPM) system for asthma and chronic obstructive pulmonary disease (COPD) in the US, w
Hard on the heels of the official launch of its digital disease management platform, Aptar Pharma has secured a partnership with Italian drugmaker Chiesi to deploy it in support of patients
